159 related articles for article (PubMed ID: 29361698)
1. A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38α Mitogen-Activated Protein Kinase Inhibitors.
Ansideri F; Andreev S; Kuhn A; Albrecht W; Laufer SA; Koch P
Molecules; 2018 Jan; 23(1):. PubMed ID: 29361698
[TBL] [Abstract][Full Text] [Related]
2. An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors.
El-Gokha A; Laufer SA; Koch P
Org Biomol Chem; 2015 Nov; 13(43):10699-704. PubMed ID: 26351018
[TBL] [Abstract][Full Text] [Related]
3. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
6. An Angle on MK2 Inhibition-Optimization and Evaluation of Prevention of Activation Inhibitors.
Hedström U; Norberg M; Evertsson E; Lever SR; Munck Af Rosenschöld M; Lönn H; Bold P; Käck H; Berntsson P; Vinblad J; Liu J; Welinder A; Karlsson J; Snijder A; Pardali K; Andersson U; Davis AM; Mogemark M
ChemMedChem; 2019 Oct; 14(19):1701-1709. PubMed ID: 31325352
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold.
Scior T; Domeyer DM; Cuanalo-Contreras K; Laufer SA
Curr Med Chem; 2011; 18(10):1526-39. PubMed ID: 21428890
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
11. Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: enantioselective synthesis and biological evaluation.
Bühler S; Goettert M; Schollmeyer D; Albrecht W; Laufer SA
J Med Chem; 2011 May; 54(9):3283-97. PubMed ID: 21449619
[TBL] [Abstract][Full Text] [Related]
12. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors.
Abu Thaher B; Koch P; Schattel V; Laufer S
J Med Chem; 2009 Apr; 52(8):2613-7. PubMed ID: 19301816
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships of 4-fluorophenyl-imidazole p38α MAPK, CK1δ and JAK2 kinase inhibitors.
Seerden JP; Leusink-Ionescu G; Woudenberg-Vrenken T; Dros B; Molema G; Kamps JA; Kellogg RM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3412-8. PubMed ID: 24930833
[TBL] [Abstract][Full Text] [Related]
14. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
[TBL] [Abstract][Full Text] [Related]
16. From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors.
Heider F; Haun U; Döring E; Kudolo M; Sessler C; Albrecht W; Laufer S; Koch P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29036906
[TBL] [Abstract][Full Text] [Related]
17. Modular Synthesis of Di- and Trisubstituted Imidazoles from Ketones and Aldehydes: A Route to Kinase Inhibitors.
de Toledo I; Grigolo TA; Bennett JM; Elkins JM; Pilli RA
J Org Chem; 2019 Nov; 84(21):14187-14201. PubMed ID: 31460764
[TBL] [Abstract][Full Text] [Related]
18. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Kong TT; Zhang CM; Liu ZP
Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.
Albrecht W; Unger A; Bauer SM; Laufer SA
J Med Chem; 2017 Jul; 60(13):5290-5305. PubMed ID: 28613871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
